of Sheldon Krimsky's published works are available for download in PDF
format from this Web site. Such works will have a PDF icon next to them.
Please note that you will need Adobe Acrobat Reader in order to download
these files. If you do not have this software, download it now:
To see selected publications in the areas of Science & Ethics, Biotechnology, Endocrine Disruptors, or Risk Analysis please click on the corresponding link on the menu bar.
Full List of Publications
214. Conflicts of interest among committee members in the National Academies' genetically engineered crop study. PLOS ONE Online DOI:10.1371/journal.pone.0172317 February 28, 2017
213. Sugar Industry Science and Heart Disease Accountability in Research24(2):124-124 (2007).
212. Conflict of Interest Policies and Industry Relationships of Guidelines Development Group Members: A Cross-Sectional Study of Clinical Practice Guidelines for Depression. Accountability in Research 24(2):99-115 (2017).
211. The Arrested Development of Golden Rice: The Scientific and Social Challenges of a Transgenic Biofortified CropInternational Journal of Social Sciences Studies4(11):51-64 (November 2016).
210. Preface: CRISPR Technology, Gene Editing Ethics in Biology, Engineering & Medicine 6(3-4):235-236 (2015).
209. Crossing the Germline Barrier: The Three Genome Baby. Ethics in Biology, Engineering & Medicine 6(3-4):237-261 (2015).
208. Review: Genome Tea Leaves Los Angeles Review of Books July 17, 2016
207. An Illusory Consensus Behind GMO Health Assessment. Science, Technology & Human Values online August 2015
206. Is Ooplasm Transfer Safe for the Offspring? GeneWatch27(3); September-November, 2014
205. From caveat emptor to caveat venditor: time to stop the influence of money on practice guideline development Journal of Evaluation in Clinical Practice with L. Cosgrove, A.F. Shaughnessy, E.E. Wheeler, S.M. Peters, D.J. Freeman-Coppadge and J.R. Lexchin. Journal of Evaluation in Clinical Practice online: 19 OCT 2014 DOI: 10.1111/jep.12244.
204. Tripartite Conflicts of Interest and High Stakes Patent Extensions in the DSM-5. with Lisa Cosgrove, Emily Wheeler, Jenesse Kaitz, Scott Greenspan, and Nicole DiPentima. Psychotherapy and Psychosomatics online Jan. 22, 2014.
203. Low-Dose Toxicology: Narratives from the Science-Transcience Interface In: Powerless Science?: Science and Politics in a Toxic World Soroya Bodia and Nathalie Jas, eds. Oxford: Berghan Press, 2014.
202. Genetic Causation: A Cross Disciplinary Inquiry In: Advances in Child Development and Behavior Vol 44 Edited by Richard M. Lerner and Janette B. Benson . Walthan, MA: Academic Press, 2013.
201. Conflicts of Interest in Approvals of Additives to Food Determined to be Generally Recognized as Safe JAMA Internal Medicine with TJ. Neltner, H.M. Alger, J.T O'Reilly, L. Bero and M.V. Maffini 13(5):16-17 (May 2013)
200. On Designer Babies Tufts Medicine 72(1)44 (Summer 2013)
199. Glypho-Gate: The Seralini Affair GeneWatch26(1); January-March, 2013
198. Review: Dogmatism in Science & Medicine Social Epistemology Review & Reply Collective2(4):10-12(2013).
197. Amicus Brief filed for the Supreme Court of the United States for the respondent in State of Maryland v. King. with Jermy Gruber. Argued February 26, 2013
196. Corporate Philanthropy and Conflicts of Interest in Public Health Journal of Public Health Policyonline Nov. 2012 doi:10.1057/jphp.2012.63; 34:137-139
195. The Dilemma in Regulating Drug Advertising: Propositional versus Non-Propositional Content American Journal of Bioethics13(5):16-17 (May 2013)
193. Commoner Memoriam GeneWatchNov-Dec 2012
192. Do Conflicts of Interest Bias Research?: An Inquiry into the Funding Effect Science, Technology & Human Values September 20. 2012; DOI: 10.1177/0162243912456271; pp. 1-22.
191. A Comparison of DSM-IV and DSM-5 Panel Members' Financial Associations with Industry: A Pernicious Problem Persists. with Lisa Cosgrove. PLOS Medicine 9(3):1-4 (March 2012).
190. Toxicology in the Genome GeneWatch25(1-2)26-27 (March 2012).
189. The Short Life of a Race Drug The Lancet Vol. 379, January 14, 2012, pp. 114-115.
188 Commentary on Ethics and Community-Based Research: Responsibility, Precaution, and Transparency. In: Tortured Science: Health Studies, Ethics, and Nuclear Weapons in the United States D. Quigley, A. Lowman, and S. Wing, eds. Amityville, NY:Baywood Pub. Co., 2011.
187. Twenty Years of DNA Databanks in the U.S.t GeneWatch Vol. 24, No. 5 (Aug.-Sept. 2011), pp. 9-11.
184. Review: A neoliberal economics of science Review of Science-Mart by Philip Mirowski, Harvard University Press, 2011. American Scientist Vol. 99, No. 4, pp. 330-332 (July/August 2011)
183. Beware of gifts that come at too great a cost Nature Vol. 474, p. 129 (June 9, 2011).
180. The Moral Education of Journal Editors Academe 96:(6):39-42 (Nov.-Dec. 2010)
179. Combating the Funding Effect in Science: What's Beyond Transparency? Stanford Law & Policy Review Vol. XXI, pp. 101-123 (2010).
178. Review of 3 books on clinical trials. Help, Harm and Human Subjects When Experiments Travel; Exploitation and Developing Countries: The Ethics of Clinical Research; Chasing Medical Miracles American Scientist Jan.-Feb. 2010, pp.73-75.
177. An Analysis of Toxicology and Medical Journal Conflict-Of-Interest Policies Accountability in Research with Erin Sweet 16:235-253 (2009).
176. Stop this Stealth Advertising New Scientist 202(2711):24-25 (June 5, 2009)
175. Developing Unbaised Diagnostic and Treatment Guidelines in Psychiatry-Letter New England Journal of Medicine with L. Cosgrove, H.J. Bursztajn 360 (19):2035-2036 (May 7,2009)
174. Conflicts of Interest and Disclosure in the American Psychiatric Associations's Clinical Practice Guidelines Psychotherapy and Psychosomatics with L. Cosgrove, H.J. Bursztajn, M. Anaya, & J. Walker 78:228-232:(2009)
173. Editorial: Industry Support and its Relationship to Research Integirty Accountability in Research 16:75-77 (2009).
172. Pharmacrops GeneWatch22:13-16 (Jan./Feb. 2009).
170. When Sponsored Research Fails the Admissions Test: A Normative Framework In:Universities at Risk: How politics, special interests, and corporitization threaten academic integrity Edited by James L. Turk. Toronto, James Lorimer & Co.,Publishers, 2008
169. Plastics in Our Diet Scientific American18(4):30-31(2008)
166. When Conflict-of-Interest is a Factor in Scientific Misconduct Medicine & Law26:447-463 (2007).
164. Risk Communication in the Internet Age: The Rise of Disorganized Skepticism Environmental Hazards 7:157-164 (2007).
163. A New Era of DNA Collections: At What Cost to Civil Liberties? with T. Simoncelli American Constitution Society for Law and Policy(September 2007).
162. Testing Pesticides in Humans: Of Mice and Men Divided by Ten with T. Simoncelli JAMA 297(21):2405-2407 (June 6, 2007).
161. The Birth of Synthetic Biology and the Genetic Mode of Production Genetically Engineered Crops: Interim Policies, Uncertain Legislation Edited by Iain E.P. Taylor. Haworth Press, 2007
160. Publication Bias, Data Ownership, and the Funding Effect in Science: Threats to the Integrity of Biomedical Research Rescuing Science from Politics: Regulation and the Distortion of Scientific Research Edited by W. Wagner and R. Steinzor. Cambridge University Press, 2006
159. Review: Origins of the Organic Agriculture DebateIn: ISIS 97(2):378-379 (2006).
158. The Ethical and Legal Foundations of Scientific 'Conflict of Interest' Law and Ethics in Biomedical Research: Regulation, Conflict of Interest, and Liability Edited by Trudo Lemmens and Duff R. Waring. University of Toronto Press, 2006
157. Financial Ties between DSM-IV Panel Members and the Pharmaceutical Industry. with L. Cosgrove, M. Vijayaraghawan, & L. Schneider Psychotherapy and Psychosomatics 75:154-160 (2006).
156. Fraudulent Human Embryonic Stem Cell Research in South Korea: Lessons Learned. With D, B. Resnik and A. E. Shamoo. Accountability in Research 13:101-109 (2006).
155. Autonomy, Disinterest, and Entrepreneurial Science Society 43(4):22-29(May/June 2006).
154. Review: University Inc.Jennifer Washburn Academe 91(5):63-64(September/October 2005).
153. Review: Recoding Nature: Critical Perspectives on Genetic EngineeringR. Hindmarsh and G. Lawrence, eds. The Quarterly Review of Biology 80:474(2005).
152. From Asilomar to Industrial Biotechnology: Risks, Reductionism and Regulation Science as Culture 14(4):309-323(December 2005).
151. China's Gene Therapy Drug GeneWatch Vol 18, No. 6 (December 2005).
150. The Weight of Scientific Evidence in Policy and Law American Journal of Public Health (Supplement) 95(S1):S129-S136(2005).
149. Review: The Great BetrayalHorace Freeland Judson. Harcourt, Inc. 2004. Nature Medicine 11(6):591 (June 2005).
148. The Funding Effect in Science and its Implications for the Judiciary Journal of Law and Policy Vol. XIII, No.1 (2005).
146. Emergence of a Scientific and Commercial R&D Infrastructure for Human Gene Therapy. (with Christine Crofts) Human Gene Therapy16:169-177(February 2005).
145. Introduction to Special Issue of Accountability in Research on Conflict of Interest. In:Accountability in Research11:79-81(April-June 2004).
144. La Recherche Face Aux Interet Prives. French version of Science in the Private Interest. Trans. by Lena Rozenberg. Preface: La Mouche et Le Tigre, by d'Isabelle Stengers.Paris, Le Seuil, 2004.
143. Reforming Research Ethics in an Age of Multivested Science. In:Buying in or Selling Out? Donald G. Stein,ed. New Brunswick, NJ: Rutgers University Press, 2004.
142. Review: Is Fluoride Really Safe? Christopher Bryson Chemical and Engineering News 82:35-36 (August 16, 2004).
141. Small Gifts, Conflicts of Interest, and the Zero-Tolerance Threshold in Medicine. American Journal of Bioethics.3:50-52(Summer 2003).
140. Review: The Hope, Hype and Reality of Genetic EngineeringJohn C. Avise. Oxford University Press, 2004. The Quarterly Review of Biology 79:506-507 (September 2004).
139. Science on Trial GeneWatch 16(5):3-6 (September-October 2003).
138. Review: The Greatest Experiment ever Performed on Women Public Health Reports 24(3/4):479-483 (2003).
137. Implicit precaution, scientific inference, and indirect evidence: the basis for the U.S. Environmental Protection Agency's regulation of genetically modified crops. New Genetics and Society. 22:127-143(August 2003).
135. Biotechnology at the dinner table: FDA oversight of transgenic food. Annals of the American Academy of Political and Social Science. 584:80-96 (November 2002).
134. Environmental impacts of the releases of genetically modified organisms. Encyclopedia of Pest Management. David Pimental, ed. N.Y.: Marcel Dekker, Inc., 2002.
133. Ethical issues involving the production, planting, and distribution of genetically modified crops. Engineering the Farm. Edited by Marc Lappe and Britt Bailey. Boulder, CO: Island Press, 2002.
132. An Epistemological Inquiry into the Endocrine Disruptor Hypothesis. Annals of the New York Academy of Sciences 948:130-142(2002).
131. Commentary on the retraction of scientific articles. Nature Genetics 30:139(February 2002).
130. Endocrine disruptors--A controversy in science and policy: Summary and research needs. Neurotoxicology 22:557-558 (October 2001).
129. Patentability of biotechnology inventions under the PTO utility guidelines: Still uncertain after all these years. Journal of Biolaw & BioBusiness. Special Supplement: Intellectual Rights and Patent Rights 2001 (with Warren A. Kaplan).
128. Japanese edition of Hormonal Chaos 2001. Tokyo: Fujiwara Publishing Co.
127. Journal Policies on Conflict of Interest: If this is the Therapy, What's the Disease [Editorial]. Psychotherapy and Psychosomatics 70:115-117(2001).
126. Hormone Disruptors: A Clue to Understanding the Environmental Causes of Disease. Environment 43:22-31(June 2001).
125. The RDNA Wars. Review of The Recombinant DNA Controversy: A Memoir by Donald S. Fredrickson. American Scientist 89:564-565(November-December 2001).
124. Conflict of Interest Policies in Science and Medical Journals: Editorial Practices and Author Disclosures. (with L.S. Rothenberg). Science and Engineering Ethics 7:205-218(April 2001).
123. Transdisciplinarity for Problems at the Interstices of Disciplines. In Transdisciplinarity: Recreating Integrative Knowledge, M.A. Somerville and D.J. Rapport, eds. Oxford, UK: EOLSS Publishers Co. Ltd., 2000, pp.109-114.
122. Scientific journals and their authors' financial interests (reprinted). In: The Commercialization of Genetics Research. T.A. Caulfield and B. William-Jones, ed. New York: Kluwer Academic Publishers, 2000.
121. Commentary on "Politics of Certainty." Science and Engineering Ethics 6(4):509-510 (2000).
120. Environmental Endocrine Hypothesis and Public Policy.In: Illness and the Environment.Steve Kroll-Smith, Phil Brown, and Valerie J. Gunter, eds. New York University Press, 2000
119. Risk Assessment and Regulation of Bioengineered Food Products. International Journal of Biotechnology. 2(1/2/3):231-238 (2000).
118. The Psychosocial Limits of Human Germline Modification.In: Engineering the Human Germline. G.Stock and J. Campbell, eds. Oxford, 2000.
117. Conflicts of Interest and Cost-effectiveness Analysis [Editorial] JAMA 282:1474-6 (October 20, 1999).
116. Hormonal Chaos: The Scientific and Social Origins of the Environmental Endocrine Hypothesis. Johns Hopkins University Press, 2000.
115. The Profit of Scientific Discovery and its Normative Implications. Chicago Kent Law Review. 75(1):15-39(1999).
114. Eureka! New Ideas in Cell Biology. Review of Society of Cells by C. Sonnenschein & A. Soto. BioScience. 49(9):747-8(September 1999).
113. The Precautionary Approach. Forum for Applied Research & Public Policy 13(3):35-38(Fall 1998).
112. Transgenic Agriculture: Biotechnology and International Trade. Journal of Science and Technology Law 4(Spring 1998).
111. Review: Research Misconduct: Issues, Implications and Strategies, E. Altman and P. Hernon, eds. NEJM 339(8):568(August 20, 1998).
110. Financial Interest and its Disclosure in Scientific Publicatons. (w. L.S. Rothenberg). JAMA 280(3):225-226(July 15, 1998).
109. Review: The Biotech Century: Harnessing the Gene and Remaking the World. Nature 393:31-32(May 7, 1998).
108. The Cultural and Symbolic Dimensions of Agricultural Biotechnology, adapted for Private Science: Biotechnology and the Rise of the Molecular Sciences, Arnold Thackray, ed. University of Pennsylvania Press, 1998.
107. Scientific Journals and Their Authors' Financial Interests: A Pilot Study (w. L.S Rothenberg, P. Stott, and G. Kyle). Psychotherapy and Psychosomatics 67(4-5):194-201(1998). Reprinted in: The Commercialization of Genetic Research T.A. Caulfield and B. Williams-Jones, eds. New York: Kluwer, 1999.
106. Review. Technical Trajectories and the Human Environment. J.H. Ausubel and H.D. Langford, eds. National Academy Press, Washington D.C., 1997; Linking Science and Technology to Society's Environmental Goals. Policy Division, National Research Council, National Academy Press. Washington D.C., 1996. Nature Biotechnology 15:1014-1015(October 1997).
105. Review. Enabling the Safe Use of Biotechnology: Principles and Practice and Appropriate Oversight for Plants with Inherited Traits for Resistance to Pests. Environment 39(5):27-30(June 1997).
104. Revolution of Evolution? [In Biotechnology] Future. Special Edition on Biotechnology, II May 1997, pp. 14-17.
103. Review. Dealing with Risk by Howard Margolis. The Annals of the American Academy of Political and Social Science. 554:230-231(Nov.1997).
102. Regulatory Oversight of Genetically Engineered Microorganisms: Has Regulation Inhibited Innovation? (with R. Wrubel and M. Anderson). Environmental Management 21(4)571-586(1997).
101. Financial Interest of Authors in Scientific Journals: A Pilot Study of 14 Publications (with Rothenberg, Stott and Kyle). Science and Engineering Ethics 2(4):395-410(1996).
100. Three Food Safety Issues: Life Cycle of Technical Controversies and the Social Selection of Risks. Working Paper #3. Center for Agriculture, Food and Environment; Tufts University School of Nutrition. October 1995.
99. Commentary: "The Hazards of Whistleblowers and on Some Problems of Young Biomedical Scientists in our Time" by John Edsall. Science and Engineering Ethics 1(4):341-344(1995).
98. Risk Assessment of Genetically Engineered Microorganisms: From Genetic Reductionism to Ecological Modeling. Prepared for the International Society for the History and Philosophy of the Biological Sciences, Leuven, Belgium, July 20, 1995.In: Coping with Deliberate Release: The Limits of Risk Assessment Ad van Dommelon, ed. Tilberg/Buenos Aires: International Center for Human & Public Affairs, 1996.
97. Review of Gene Wars: Science, Politics and the Human Genome by Robert Cooke-Deegan. In Politics and the Life Sciences 15(1):130-1(Feb. 1996).
96. A Role for Standardized Microcosms in the Risk Assessment of Genetically Engineered Microorganisms. BioScience 45(9):590-599 (October, 1995). (with R.P. Wrubel, S.B. Levy, R.E. Wetzler, & B. Marshall).
95. Editorial. The Future of the Recombinant DNA Advisory Committee. Human Gene Therapy 5:1313-4(November 1994).
94. Science, Money and Innovation. [Review]. Profits of Science by Robert Teitelman. Forum for Applied Research and Public Policy. 10(4):146-7(Winter1995).
93. The Environmental Endocrine Hypothesis and Public Policy. Comments on Toxicology5(4-5):487-502. 1996.
92. The Cultural and Symbolic Dimensions of Agricultural Biotechnology. In Issues in Agricultural Bioethics, T.B. Mepham, G.A. Tucker, J. Wiseman, eds. Nottingham: Nottingham University Press, 1995, pp. 1-18.
91. The Business of Research. (w. Ruth Hubbard) Hastings Center Report25(1):41-43 (Jan/Feb 1995).
90. Science, Society, and the Expanding Boundaries of Moral Discourse. Science, Politics and Social Practice. Boston Studies in the Philosophy of Science. Dordrecht:Kluwer, 1995.
89. Agricultural Biotechnology & the Environment. (with Roger Wrubel). Champagne, IL: University of Illinois Press. 1996.
88. Review: Democratic Values and Technological Choices. Stuart Hill. Stanford Univ. Press, 1992. In American Scientist 82:90-91(January-February 1994).
87. Review: The Social Costs of Genetic Welfare by Marque-Luisa Miringoff. Rutgers Univ. Press 1991. In Social Science Quarterly 74(1):230-232 (March 1993).
86. Review: Gene Mapping: Using Law and Ethics as Guides, George G. Annas and Sherman Elias, eds. 1992. In Social Science & Medicine 38(1):199-200.
85. Risk Analysis and Public Policy. Environment. 35(2):5;40-41(March 1993).
84. Field Testing Transgenic Plants: An Analysis of USDA's Environmental Assessments. (with R. Wrubel and R. Wetzler). BioScience 42(4):280-289 (April 1992).
83. Evaluating Risk Communication: Narrative versus Technical Presentations of Information about Radon (with D. Golding and A. Plough). Risk Analysis 12(1):27-35 (1992).
82. Social Theories of Risk. (with D. Golding, ed.) Westport, CT: Praeger, 1992.
81. Factoring Risk Into Environmental Decision Making (with D. Golding) In: Environmental Decision Making: A Multidisciplinary Perspective. R. Chechile and S. Carlisle, eds. NY: Van Nostrand Reinhold, 1991.
80. Techno farming [Review]. Plants, Power and Profit by L. Busch et al. Nature 350:568 (April 18, 1991).
79. Academic Corporate Ties in Biotechnology: A Quantitative Study. Science,Technology &Human Values16(3):275-287 (Summer 1991).
78. Biotechnics and Society: The Rise of Industrial Genetics. NY: Praeger, 1991.
77. Human Gene Therapy: Must We Know Where to Stop before We Start Human Gene Therapy1(2):171-173(Summer 1990).
76. Translation of Ch. 3 "Release of Gentically Engineered Organisms into the Environment" from Environmental Hazards into Danish. Udsactning Af Genspejsede Organismer. 1 Miljoet "Is Minus-Sagen." Jesper Toft, ed. Copenhagen: Noah, 1988. Gen Debat 3.
75. Biotechnology's Benefits Can Only Be Assured Through Controls. Opposing Viewpoints. Sources. Science & Technology. Vol. 1. St. Paul, MN: Greenhaven Press, 1987.
74. Assessing the Progress of the Genetics Revolution. 1988 Telegen Annual. NY: Bowker Pub. Co., 1989.
73. Fetal Research in the United States: A Historical and Normative Perspective. In Artificial Procreation: The State of Ethics and Law. C. Byk, ed. Paris: Masson, 1989.
72. Controlling Risk in Biotech. (with K. Bergmann, N. Conell, S. Schulman, & N. Wilker). Technology Review 92(5):62-70 (July 1989).
71. Biopolitics:Looking for a Home [Commentary]. Issues in Science & Technology 4(4):29(Summer 1988).
70. Risky Science: Is Anybody Watching the Experimental AIDS Mouse? The Scientist May 16, 1988, pp. 11-12.
69. Carrying the Baconian Torch [Review]. Controlling Life: Jacques Loeb and the Engineering Ideal in Biology. In Hastings Center Report, June.July 1988.
68. Jeux Sans Frontieres [Review]. The Biotechnology Revolution: An International Perspective by A.M. Russell. NY: St. Martin's Press, 1988. InNature334:111-112(July 14, 1988).
67. Science, Biopolitics and Risk: Margins of Uncertainty Politics and the Life Sciences7:140-142 (February 1989).
66. University Entrepreneurship and the Public Purpose. Biotechnology: Professional Issues and Social Concerns. P. DeForest, M.S. Frankel, J.S. Poindexter, and V. Weil,eds. Washington DC: American Association for the Advancement of Science. October 1988.
65. Environmental Release of Genetically Engineered Organisms: Recasting the Debate (w. K. Bergman, N. Connell, S. Shulman, N. Wilker).GeneWatch 5(2-3):1-3;6-7(1988).
64. Environmental Hazards: Communicating Risks as a Social Process. Auburn House Pub. Co., 1988 (w. A. Plough).
63. Review:Biotechnology: The University-Industry Complex by Martin Kenney. New Haven: Yale University Press, 1987. In American ScientistSept-Oct. 1987, p. 549.
62.The Emergence of Risk Communication Studies: Social and Political Context (w. A. Plough). Science, Technology & Human Values 12(3&4):4-10(Summer-Fall 1987).
61. Science and Politics in Transition: Making Sense of Biotechnology Policy [Review]: Biotechnology in Society, J.G.Perpich (ed.); and Biotechnology: Implications for Public Policy, S. Panem (ed.). In Politics and the Life Sciences 6(1):122-124 (Aug.1987).
60. Review: Read the Label: Reducing the Risk by Providing Information by Susan Hadden. In Science, Technology and Human Values 12(2):65-66(Spring 1987).
59. The New Corporate Identity of the American University. Alternatives 14(2):20-29 (May/June 1987).
58. Beyond the Technical Problems of Intentional Release (with D. Andow, J. Doyle, and C. Nader). In Prospects for Physical and Biological Containment of Genetically Engineered Organisms, James W. Gillett (ed.). Ecosystems Research Center Report no. 114, March 1987.
57. The Socio-Historical Context of the Debate Over Deliberate Release. In Application of Biotechnology: Environmental and Policy Issues. John R. Fowle III (ed.). Washington, D.C.: Westview Press, 1987.
56. The Regulatory Quandary Over Biotechnology. Proceedings of the Washington International Conference on Biotechnology. April 21-22, 1986.
55. Research Under Community Standards: Three Case Studies. Science, Technology & Human Values.11(3):14-33 (Summer 1986).
54. Biologists Under Control [Review]. The Politics of Regulating Recombinant DNA Research in Britain by David Bennett, Peter Glasner and David Travis and Cloning and the Constitution: An Inquiry into Governmental Policymaking and Genetic Experimentation by Ira H. Carmen.Nature 21:735-736(June 19, 1986).
53. Legislacion: Desarrollo en EE.UU. (1973-1982). La Ingenieria Genetica y Sus Aplicaciones. Jose R. Pellon (ed.). Traducido al castellano por Miguel Zamora. Zaragoza, Spain, Acribia, S.A., 1986, pp.199-215.
52. Local Control of Research Involving Chemical Warfare Agents. In: Governing Science and Technology in a Democracy. Malcolm L. Goggin (ed.). Knoxville, TN: University of Tennessee Press, 1986, 194-217.
51. The New Corporate Identity of the American University. Proceedings of an International Symposium: Universities in the Twenty-first Century. October 23-25, 1985, University of New Hampshire, Durham, New Hampshire.
50. Social Responsibility in an Age of Synthetic Biology: Beyond Biohazards. InThe Gene-splicing Wars: Reflections on the Recombinant DNA Controversy. R. Zilinskas and B.K. Zimmerman, (eds.). N.Y.:Macmillan Pub. Co., 1986.
49. United States and Canadian Governmental Regulations Concerning Biohazardous Effluents Comprehensive Biotechnology (with A.H. Frankel), Vol 4, The Practice of Biotechnology, Murray Moo-Young, Editor-in-Chief, 1986, pp. 609-631, 2006.
48. Private Sector Science and the Community: The Morris Township-Bellcore Case. The Regulatory Environment for Science: Social Restraints and Legal Controls of Research. Marcel LaFollette (ed.). Washington, D.C.: Office of Technology Assessment, February 1986.
47. Comparison of Two Cases of Community Control of Research. The Regulatory Environment for Science: Social Restraints and Legal Controls of Research. Marcel LaFollette (ed.). Washington, D.C.: Office of Technology Assessment, February 1986.
46. The Corporate Capture of Genetic Technologies. Science for the People. Special Issue: De-coding Biotechnology. 17(3):32-37 (May/June 1985).
45. Review: The Gene Business by Edward Yoxen. The Quarterly Review of Biology 60:74-75 (March 1985).
44. The Corporate Capture of Academic Science and its Social Costs. Genetics and the Law III. Proceedings of the Third National Symposium on Genetics and the Law, April 2-4, 1984. Aubrey Milunsky and George Annas (eds.). New York: Plenum Press, 1985, pp. 45-55.
43. Regulation of Biotechnologies: State and Local Roles and Initiatives. Biotechnology and the Environment: Risk & Regulation. A.H. Teich, M.A. Levin, and J.H. Pace (eds.). Washington, D.C.: American Association for the Advancement of Science, 1985, pp. 159-177.
42. Epistemic considerations on the value of folk-wisdom in science and technology..Policy Studies Review 3(2):245-262 (February 1984).
41. Beyond Technocracy: New Routes for Citizen Involvement in Social Risk Assessment. Citizen Particpation in Science Policy. James C. Peterson, ed. Amherst, MA: Univ. Mass. Press, 1984, pp. 43-62. Reprint of J. Voluntary Action Research.
40 Pure Science and Impure Scientists: Dilemmas for Public Policy Politics in the LIfe Sciences 3(1):49-51 (August 1984)).
39. Genetic Alchemy. Japanese translation. 1984. Japanese editor, Rihito Kimura. Ie-No-Hikari Assoc. Tokyo, Japan.
38. Regulatory Policies on Biotechnology in Canada. A contracted report for the Science Council of Canada, February 1984. Published by the Council, Fall 1984.
37. Development of Biotechnology Policy and Regulations in the U.S.: 1982-1983. Telegen Annual Review. Genetic engineering abstracts. New York: Environmental Information Center, 1984.
36. Social Risk Assessment and Group Process. Group Decision Making: Interdisciplinary Perspectives. W.C. Swap, ed. Sage Pub.,1984.
35. Municipal and State Recombinant DNA Laws: History and Assessment. (with A. Baeck and J. Bolduc). Medford, MA: Dept. Urban and Environmental Policy, Tufts University, June 1982.
34. Review. Progress and Its Discontents G.A. Almond, M. Chodorow, and R.H. Pearce, eds. Environmental Professional 5(3&4),(1983).
33. Review. Alternatives to Regulation by M.S. Baram. Environmental Affairs Law Review 10(2):579-582 (1982).
32. Science Perverted: Can It Happen Here? [Review]. Politics and the Restraint of Science by L.A. Cole.Hastings Center Report 13(6):42-43 (December 1983).
31. Biotechnology and Unnatural Selection: The Social Control of Genes..Technology and Social Change A Festschrift for Eugene A. Wilkening. Gene F. Summers (ed.) Boulder, CO: Westview Press, 1983, pp. 51-70.
30. Development of Recombinant DNA Policy and Regulations in the U.S.: 1981-1982. Telegen Annual Review, Index and Yearbook, 1982. Genetic Engineering Abstracts. New York: Environmental Information Center, January1983.
29. Social Responsibility in an Age of Synthetic Biology. Environment.24(6):2-5;8-11 (July-August 1982).
28. Development of Recombinant DNA Policy and Regulations in the U.S., 1973-1980. Biotechnology Emerges:1973-1980 the Key Years. Telegen Annual Review. Genetic Engineering Abstracts. NY:Environmental Information Center, November 1982.
27. Local Monitoring of Biotechnology: The Second Wave of RDNA Laws. Recombinant DNA Bulletin 5(2):79-85 (June 1982).
26 Beyond Technocracy: New Routes fpr Citizen Involvement in Social Risk Assessment Journal of Voluntary Action Research 11(1):8-23 (Jan-Mar 1982).
25. Regulating Genetic Engineering. Published debate with Bernard Fields. The Harvard Health Letter. August, 1981.
24. The Political Economy of Environmental Issues. The Radical Teacher 7(19):6-8 (1981).
23. Genetic Alchemy: The Social History of the Recombinant DNA Controversy. Cambridge, MA: The MIT Press, 1982.
22. Patents for Life Forms sui generis: Some New Questions for Science, Law and Society Recombinant DNA Technical Bulletin 4(1):11-15 (April 1981).
21. Genetic Technology: The Future of Regulation. Proceedings of the Battelle International Conference on Genetic Engineering, April 6-10, 1981, Reston, VA.
20. Patenting of Microorganisms and Higher Life Forms: Social and Ethical Concerns..Patenting of Microorganisms: Issues and Questions. Robert F. Acker and Moselio Schaechter (eds.) Washington D.C.: American Society for Microbiology, 1981, pp. 17-22.
19. Value Issues in the Controversy over Recombinant DNA Research. A Study funded by the Program in Ethics Values in Science and Technology (EVIST), National Science Foundation. Five parts, approx. 1000 pp. The Social and Political Context, Part 1, Vol. I.; The Asilomar Period, Part 2, Vol. II; The Origins of Public Involvement, Part 3, Vol. II; Scientific and Policy Debates, Part 4, Vol. III. Papers and Essays, Part 5, Vol. IV. 1981.
18. The Ties That Bind. Published Debate with David Baltimore. Nature.283:130-131(January 10, 1980).
17. A Comparative view of state and municipal laws regulating the use of recombinant DNA molecule technology. Recombinant DNA Technical Bulletin 2(3):121-125(November 1979).
16. Book Review: Core of controversy over biohazards. The Recomnbinant DNA Debate In: Nature 282:170-171 (November 8, 1979).
15. Recombinant DNA Research: The Scope and Limits of Regulation. with David Ozonoff. American Journal of Public Health 69:1252-125 (December 1979.
14. Public Participation in the Formation of Science and Technology Policy. Report prepared under contract from the Directorate for Scientific, Technological and International Affairs (STIA), National Science Foundation, March 1979.
13. Citizen Participation in Scientific and Technological Decisionmaking. Citizen Participation Perspectives. Stuart Langton, ed. Proceedings of the National Conference on Citizen Participation, Lincoln Filene Center, Tufts University, 1979.
12. A Citizen Court in the Recombinant DNA Debate Bulletin of the Atomic Scientists34:37-43 (October 1978)
11. An Experiment in Environmental Education for Citizen Advocates. (with J. DeNeufville). Journal of Alternative Higher Education. 2(3):210-222 (Spring l978).
10. Regulating Recombinant DNA Research. Controversy: Politics of Technical Decisions. Dorothy Nelkin (ed.). Beverly Hills, CA: Sage Pub., 1978.
9. Paradigms and Politics: The Roots of Conflict over Recombinant DNA Research Proceedings of the Poynter Center, 1978 A forum held at Indiana University, November 10-12, 1977, R. P. Bareikis, ed.
8. The Recombinant DNA Controversy and the Public Interest Chemical & Engineering News 55:36-41 (May 30, 1977).
7. The Cambridge Experimentation Review Board Bulletin of the Atomic Scientists 33(5):23-27 (May 1977).
6. On Deductive Non-Nomological Explanation Philosophia Bar-Ilan University, Israel. 6(2):303-308 (June 1976).
5. On Thought Experiments Philosophical Forum (with W.D. Price) A translation and adaptation of a work by Ernst Mach (1897) "Uber Gedankenexperimente." 4(3): 446-457 (Spring 1973).
4. The Scientist as Alienated Man. Science, Technology and Freedom. W.H. Truitt and T.W.G. Solomons, eds. pp.169-176.
3. The Use and Misuse of Critical Gedankenexperimente Zeitschrift fur Algemeine Wissenschaftstheorie 4(2):323-334 (1972), Dusseldorf, Germany.
2. The Multiple World Experiment and Absolute Space. Nous 6(3):266-273 (September l972).
1. The Gamma Function and Stirling's Approximation The Brooklyn College Journal of Science 1963.
Home | Bio | Publications | Science & Ethics Publications | Biotechnology Publications | Endocrine Disruptors Publications | Risk Analysis Publications | Books | Commentaries | Book Reviews | Courses | Links